Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Syndicate	Biohaven Pharmaceutical files to sell 115,836 shares of common stock for holders 17:03 03/05/21 03/05 17:03 03/05/21 17:03 BHVN Biohaven Pharmaceutical $84.03 / +6.29 (+8.09%) ShowHide Related Items >><< Company News Street Research Earnings BHVN Biohaven Pharmaceutical $84.03 / +6.29 (+8.09%) 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains 01/25/21 Biohaven sees Q4 NURTEC ODT net product revenue $35M 01/19/21 Biohaven Pharmaceutical falls -9.2% 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial BHVN Biohaven Pharmaceutical $84.03 / +6.29 (+8.09%) 03/02/21 Mizuho Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler 01/25/21 Piper Sandler Piper recommends buying Biohaven Pharmaceutical shares at current levels 01/19/21 Canaccord Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord BHVN Biohaven Pharmaceutical $84.03 / +6.29 (+8.09%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89)

Tuesday
Recommendations	Axsome Therapeutics price target lowered to $118 from $120 at Mizuho » 06:49 03/02/21 03/02 06:49 03/02/21 06:49 AXSM Axsome Therapeutics / + Mizuho analyst Vamil… Mizuho analyst Vamil Divan lowered the firm's price target on Axsome Therapeutics to $118 from $120 and keeps a Buy rating on the shares following the company's Q4 results. The analyst expects AXS-05 to obtain a Priority Review, and expects the stock to rise as investors come to appreciate AXS-05's potential. ShowHide Related Items >><< Company News Street Research Earnings On The Fly AXSM Axsome Therapeutics / + 03/01/21 Axsome Therapeutics announces 2021 anticipated milestones 03/01/21 Axsome Therapeutics expects cash to fund operations into at least 2024 01/04/21 Myovant Sciences names David Marek as CEO, succeeding Lynn Seely 12/31/20 Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05 AXSM Axsome Therapeutics / + 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Jefferies Axsome Therapeutics initiated with a Buy at Jefferies 12/15/20 Mizuho Axsome Therapeutics initiated with a Buy at Mizuho 12/03/20 Cantor Fitzgerald Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald AXSM Axsome Therapeutics / + 03/01/21 Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) 11/05/20 Axsome Therapeutics reports Q3 EPS (61c), consensus (57c) AXSM Axsome Therapeutics / + 12/01/20 Fly Intel: Pre-market Movers
Recommendations	Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho » 06:48 03/02/21 03/02 06:48 03/02/21 06:48 BHVN Biohaven Pharmaceutical $86.74 / +1.64 (+1.93%) Mizuho analyst Vamil… Mizuho analyst Vamil Divan raised the firm's price target on Biohaven Pharmaceutical to $103 from $93 and keeps a Buy rating on the shares following the company's :strong" Q4 results. ShowHide Related Items >><< Company News Street Research Earnings Events BHVN Biohaven Pharmaceutical $86.74 / +1.64 (+1.93%) 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains 01/25/21 Biohaven sees Q4 NURTEC ODT net product revenue $35M 01/19/21 Biohaven Pharmaceutical falls -9.2% 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial BHVN Biohaven Pharmaceutical $86.74 / +1.64 (+1.93%) 03/01/21 Piper Sandler Biohaven price target raised to $110 from $90 at Piper Sandler 01/25/21 Piper Sandler Piper recommends buying Biohaven Pharmaceutical shares at current levels 01/19/21 Canaccord Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord 01/19/21 Mizuho Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho BHVN Biohaven Pharmaceutical $86.74 / +1.64 (+1.93%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) 03/02/21 41st Annual Healthcare Virtual Conference

Over a week ago
Recommendations	Biohaven price target raised to $110 from $90 at Piper Sandler » 12:08 03/01/21 03/01 12:08 03/01/21 12:08 BHVN Biohaven Pharmaceutical $86.20 / +1.1 (+1.29%) Piper Sandler analyst… Piper Sandler analyst Tyler Van Buren raised the firm's price target on Biohaven Pharmaceutical to $110 from $90 and keeps an Overweight rating on the shares following the company's Q4 results. "By anyone's standards, Biohaven's launch of Nurtec over the past year has been extremely effective," Van Buren tells investors in a research note. With 89% commercial coverage, leads in new and productive prescribers, and a likely Q2 prevention approval, Biohaven might be able to attain a leading share against competitor Ubrelvy by end of the year, says the analyst. ShowHide Related Items >><< Company News Street Research Earnings Events BHVN Biohaven Pharmaceutical $86.20 / +1.1 (+1.29%) 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains 01/25/21 Biohaven sees Q4 NURTEC ODT net product revenue $35M 01/19/21 Biohaven Pharmaceutical falls -9.2% 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial BHVN Biohaven Pharmaceutical $86.20 / +1.1 (+1.29%) 01/25/21 Piper Sandler Piper recommends buying Biohaven Pharmaceutical shares at current levels 01/19/21 Canaccord Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord 01/19/21 Mizuho Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho 01/19/21 H.C. Wainwright Biohaven price target lowered to $111 from $121 at H.C. Wainwright BHVN Biohaven Pharmaceutical $86.20 / +1.1 (+1.29%) 03/01/21 Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) 03/02/21 41st Annual Healthcare Virtual Conference 03/01/21 Biohaven Pharmaceutical - BHVN
Conference/Events	Cowen to hold a virtual conference » 09:07 03/01/21 03/01 09:07 03/01/21 09:07 QGEN Qiagen $50.02 / -0.33 (-0.66%) , SLN Silence Therapeutics $28.01 / + (+0.00%) , BIIB Biogen $272.68 / -4.95 (-1.78%) , AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) , GBT Global Blood Therapeutics $42.60 / -0.885 (-2.04%) , OCUL Ocular Therapeutix $18.40 / +0.27 (+1.49%) , ACAD Acadia $49.00 / +1.605 (+3.39%) , PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) , ZTS Zoetis $155.41 / -1.14 (-0.73%) , QTNT Quotient $4.49 / -0.06 (-1.32%) , DVAX Dynavax $8.75 / +0.595 (+7.30%) , OTRK Ontrak $59.13 / -3.3 (-5.29%) , ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) , PFE Pfizer $33.49 / -0.335 (-0.99%) , BLFS BioLife Solutions $39.29 / +0.07 (+0.18%) , CHRS Coherus Biosciences $16.22 / +0.97 (+6.36%) , SAGE Sage Therapeutics $85.02 / +1.45 (+1.74%) , CERS Cerus $6.14 / -0.325 (-5.03%) , EXEL Exelixis $21.70 / -0.26 (-1.18%) , ALNY Alnylam $147.94 / +1.4 (+0.96%) 41st Annual Healthcare… 41st Annual Healthcare Virtual Conference will be held on March 1-4 beginning at 9:10 am on March 1. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Rumors Options ZTS SLN SAGE QTNT QGEN PFE PACB OTRK OCUL GBT EXEL DVAX CHRS CERS BLFS BIIB AXSM ARQT ALNY ZTS Zoetis $155.41 / -1.14 (-0.73%) 02/22/21 Zoetis receives European Commission marketing authorization for Solensia 12/09/20 Zoetis raises quarterly dividend by 25% to 25c per share 11/12/20 Zoetis receives European Commissionmarketing authorization for Librela SLN Silence Therapeutics $28.01 / + (+0.00%) 02/26/21 Silence, Mallinckrodt initiate work on third target in collaboration SAGE Sage Therapeutics $85.02 / +1.45 (+1.74%) 01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 11/27/20 Sage Therapeutics trading resumes 11/27/20 Sage Therapeutics to resume trading at 8 am ET QTNT Quotient $4.49 / -0.06 (-1.32%) 03/01/21 Quotient announces equity awards 02/23/21 Quotient names Manuel Mendez as CEO, succeeding Franz Walt 12/22/20 Quotient COO Ed Farrell to resign 12/10/20 Quotient receives FDA request for testing data on Initial SDS Microarray, MosaiQ QGEN Qiagen $50.02 / -0.33 (-0.66%) 02/24/21 Qiagen, Inovio expand collaboration to develop NGS companion diagnostic 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 02/10/21 Qiagen CEO says will consider potential 'bolt-on acquisitions' 02/09/21 Quidel CEO tells Bloomberg won't enter deal without 'obvious strategic fit' PFE Pfizer $33.49 / -0.335 (-0.99%) 03/01/21 Flowserve supports Pfizer in production of COVID-19 vaccine 02/26/21 Pfizer: EMA accepts MAA for 20-valent pneumococcal conjugate vaccine candidate 02/26/21 Pfizer, Opko Health: EMA accepts marketing application for somatrogon 02/25/21 Pfizer, BioNTech to evaluate safety of third dose of COVID-19 vaccine PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 02/24/21 Children's Mercy Kansas City implements four PacBio Sequel IIe Systems 02/18/21 Pacific Biosciences announces LabCorp's addition of PacBio Sequel II Systems 02/10/21 Pacific Biosciences reports Q4 EPS 40c, consensus 32c 02/10/21 Pacific Biosciences announces $900M investment from SoftBank OTRK Ontrak $59.13 / -3.3 (-5.29%) 10/29/20 Ontrak acquires behavior change platform LifeDojo 10/13/20 Ontrak rises after announcing launch of Ontrak-CI program OCUL Ocular Therapeutix $18.40 / +0.27 (+1.49%) 03/01/21 Ocular Therapeutics says 1st patient dosed in phase 2 clinical trial of OTX-DED 01/20/21 Ocular Therapeutix to present new OTX-TIC data at Glaucoma 360 Forum 12/22/20 Ocular Therapeutix submits Dextenza sNDA to FDA 11/04/20 Ocular Therapeutix receives permanent category I CPT code from AMA GBT Global Blood Therapeutics $42.60 / -0.885 (-2.04%) 02/05/21 Global Blood Therapeutics announces employment inducement grants 02/04/21 Global Blood Therapeutics announces expanded access protocol for Oxbryta 01/27/21 Global Blood Therapeutics' Oxbryta validated by EMA 01/07/21 Global Blood Therapeutics announces employment inducement grants EXEL Exelixis $21.70 / -0.26 (-1.18%) 02/26/21 Exelixis: Ipsen receives positive CHMP opinion for CABOMETYX/OPDIVO combo 02/25/21 Exelixis announces Breakthrough Therapy Designation granted to cabozantinib 02/14/21 Exelixis announces Phase 2 results for CABOMETYX in metastatic PRCC 02/12/21 Exelixis announces 'positive' final data for Phase 1 cabozantinib trial DVAX Dynavax $8.75 / +0.595 (+7.30%) 02/19/21 Dynavax announces European Marketing Authorization for Heplisav 02/04/21 Dynavax, India's Serum Institute begin dosing in Phase 1 Tdap vaccine trial 02/01/21 Dynavax, CEPI announce $99M in funding for CpG 1018 adjuvant manufacturing 02/01/21 Dynavax and Valneva reports UK Government order for VLA2001 CHRS Coherus Biosciences $16.22 / +0.97 (+6.36%) 02/17/21 Coherus Biosciences announces acceptance of BLA filing for CHS-1420 02/16/21 Coherus CFO Jean-Frederic Viret to resign 02/02/21 Coherus Biosciences to receive $50M strategic investment 02/01/21 Coherus Biosciences, Junshi Biosciences collaborate to co-develop toripalimab CERS Cerus $6.14 / -0.325 (-5.03%) 02/24/21 Cerus forms Joint Venture for its Intercept Blood System in China 10/13/20 Cerus awarded five-year contract with FDA with a value of $11.1M BLFS BioLife Solutions $39.29 / +0.07 (+0.18%) 02/16/21 BioLife Solutions promotes Marcus Schulz to Chief Revenue Officer 12/01/20 BioLife Solutions participates in iVexSol Series A Funding 12/01/20 BioLife Solutions announces two new co-investments with Casdin Capital 09/21/20 BioLife Solutions to acquire SciSafe for $30M in cash and stock BIIB Biogen $272.68 / -4.95 (-1.78%) 02/03/21 Biogen sees FY21 adjusted R&D expense $2.35B-$2.45B 02/03/21 Biogen CEO sees 'a financial reset in 2021' 02/01/21 Biogen announces FDA approval of PLEGRIDY intramuscular administration 01/29/21 Biogen, Eisai announce 3-month extension of review period for aducanumab BLA AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 03/01/21 Axsome Therapeutics announces 2021 anticipated milestones 03/01/21 Axsome Therapeutics expects cash to fund operations into at least 2024 01/04/21 Myovant Sciences names David Marek as CEO, succeeding Lynn Seely 12/31/20 Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05 ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) 02/18/21 Arcutis Biotherapeutics appoints Courtney Barton as CCO, chief of staff 01/20/21 Arcutis to advance topical roflumilast foam into Phase 3 development 01/13/21 Arcutis initiaties Phase 3 clinical trials of topical roflumilast cream 01/11/21 Arcutis Biotherapeutics appoints Matthew Moore as CBO ALNY Alnylam $147.94 / +1.4 (+0.96%) 01/07/21 Alnylam trading resumes 01/07/21 Alnylam announces HELIOS-A study met primary, both secondary endpoints 01/07/21 Alnylam trading halted, news pending 12/21/20 Alnylam appoints Tolga Tanguler to Chief Commercial Officer role QGEN SLN BIIB AXSM GBT OCUL ACAD PACB ZTS QTNT DVAX OTRK ARQT PFE BLFS CHRS SAGE CERS EXEL ALNY QGEN Qiagen $50.02 / -0.33 (-0.66%) 02/19/21 Berenberg Qiagen price target raised to EUR 56 from EUR 52 at Berenberg 02/09/21 William Blair Quidel, Qiagen merger would not make sense, says William Blair 02/09/21 Wells Fargo Qiagen shares should be sold on latest merger talk, says Wells Fargo 02/09/21 Citi Merger with Qiagen would benefit Quidel, says Citi SLN Silence Therapeutics $28.01 / + (+0.00%) 11/18/20 BTIG Silence Therapeutics initiated with a Buy at BTIG BIIB Biogen $272.68 / -4.95 (-1.78%) 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald 02/08/21 Citi Expert sees Biogen aducanumab approval 50/50 at best, says Citi 02/04/21 SVB Leerink Biogen price target lowered to $380 from $430 at SVB Leerink 02/04/21 Credit Suisse Biogen price target lowered to $338 from $350 at Credit Suisse AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Jefferies Axsome Therapeutics initiated with a Buy at Jefferies 12/15/20 Mizuho Axsome Therapeutics initiated with a Buy at Mizuho 12/03/20 Cantor Fitzgerald Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald GBT Global Blood Therapeutics $42.60 / -0.885 (-2.04%) 02/25/21 William Blair Global Blood Therapeutics downgraded to Market Perform at William Blair 01/27/21 Oppenheimer Global Blood Therapeutics' MAA accepted ahead of schedule, says Oppenheimer 01/20/21 Piper Sandler Global Blood downgraded to Neutral from Overweight at Piper Sandler 12/15/20 H.C. Wainwright Global Blood Therapeutics assumed with a Buy at H.C. Wainwright OCUL Ocular Therapeutix $18.40 / +0.27 (+1.49%) 02/12/21 Piper Sandler Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler 12/30/20 JMP Securities Ocular Therapeutix price target raised to $30 from $20 at JMP Securities 12/28/20 Fly Intel: Top five analyst calls 12/28/20 H.C. Wainwright Ocular Therapeutix downgraded to Neutral from Buy at H.C. Wainwright ACAD Acadia $49.00 / +1.605 (+3.39%) 02/25/21 Mizuho Acadia price target raised to $70 from $69 at Mizuho 12/29/20 Cantor Fitzgerald Acadia price target raised to $70 from $61 at Cantor Fitzgerald 12/15/20 Mizuho Acadia initiated with a Buy at Mizuho 11/16/20 Raymond James Acadia upgraded to Strong Buy from Outperform at Raymond James PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 02/11/21 Cantor Fitzgerald Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald 02/11/21 Piper Sandler Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler 01/15/21 Piper Sandler Pacific Biosciences price target raised to $20 from $12 at Piper Sandler 01/12/21 Cantor Fitzgerald Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald ZTS Zoetis $155.41 / -1.14 (-0.73%) 02/17/21 Credit Suisse Zoetis price target raised to $203 from $197 at Credit Suisse 11/12/20 Truist Zoetis price target raised to $170 from $160 at Truist 11/06/20 Barclays Zoetis price target raised to $189 from $175 at Barclays 09/21/20 Atlantic Equities Zoetis initiated with an Overweight at Atlantic Equities QTNT Quotient $4.49 / -0.06 (-1.32%) 05/18/20 Cowen Quotient partner update suggests progress on antibody front, says Cowen DVAX Dynavax $8.75 / +0.595 (+7.30%) 02/08/21 Evercore ISI Dynavax had 'big vaccine update week,' says Evercore ISI 02/01/21 Cowen Dynavax undervalued for potential of Heplisav and COVID vaccine, says Cowen 02/01/21 H.C. Wainwright Dynavax price target raised to $15 from $14 at H.C. Wainwright 11/06/20 H.C. Wainwright Dynavax price target raised to $14 from $12 at H.C. Wainwright OTRK Ontrak $59.13 / -3.3 (-5.29%) 01/05/21 Benchmark GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021 01/04/21 B. Riley Securities Ontrak price target raised to $110 from $100 at B. Riley Securities 11/18/20 B. Riley Securities Ontrak initiated with a Buy at B. Riley Securities 10/02/20 Canaccord Ontrak analysis points to significant upside for shares, says Canaccord ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) 02/02/21 Truist Arcutis Biotherapeutics price target raised to $48 from $38 at Truist 02/01/21 Cowen Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen 01/28/21 JonesTrading Arcutis Biotherapeutics initiated with a Buy at JonesTrading 11/09/20 Goldman Sachs Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs PFE Pfizer $33.49 / -0.335 (-0.99%) 02/23/21 B. Riley Securities B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho BLFS BioLife Solutions $39.29 / +0.07 (+0.18%) 12/28/20 Northland BioLife Solutions price target raised to $55 from $35 at Northland 11/09/20 KeyBanc BioLife Solutions initiated with an Overweight at KeyBanc 10/19/20 B. Riley Securities BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities 09/23/20 B. Riley Securities BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR CHRS Coherus Biosciences $16.22 / +0.97 (+6.36%) 02/25/21 Citi Coherus Biosciences price target lowered to $27 from $30 at Citi 02/25/21 H.C. Wainwright Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright 11/19/20 Mizuho Coherus Biosciences price target lowered to $30 from $35 at Mizuho 08/21/20 Mizuho Express Scripts exclusion does not impact Coherus, says Mizuho SAGE Sage Therapeutics $85.02 / +1.45 (+1.74%) 02/26/21 Mizuho Sage Therapeutics downgraded to Neutral from Buy at Mizuho 02/25/21 Oppenheimer Sage Therapeutics price target raised to $102 from $90 at Oppenheimer 02/25/21 H.C. Wainwright Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright 02/24/21 Stifel Stifel cuts Sage target to $121, reiterates Buy after quarterly results CERS Cerus $6.14 / -0.325 (-5.03%) 11/30/20 Cowen Value proposition for Cerus' Intercept cryo 'clear,' says Cowen 10/07/20 BTIG Cerus assumed with a Buy at BTIG 08/19/20 Stifel Cerus story about platelets, not convalescent plasma, says Stifel 08/10/20 Cowen Cerus multi-layered sales growth trajectory 'convincing,' says Cowen EXEL Exelixis $21.70 / -0.26 (-1.18%) 02/15/21 Piper Sandler Exelixis price target raised to $36 from $33 at Piper Sandler 01/25/21 Piper Sandler Piper says Exelixis could have 'blockbuster opportunity' with XL102 01/22/21 Piper Sandler Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler 01/20/21 William Blair Exelixis selloff on competitive concerns an 'overreaction,' says William Blair ALNY Alnylam $147.94 / +1.4 (+0.96%) 02/22/21 Guggenheim Alnylam downgraded to Neutral from Buy at Guggenheim 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 Barclays Alnylam price target raised to $196 from $162 at Barclays 02/12/21 Citi Alnylam downgraded to Neutral from Buy at Citi ZTS SAGE QTNT QGEN PFE PACB OTRK OCUL GBT EXEL DVAX CHRS CERS BLFS BIIB AXSM ARQT ALNY ACAD ZTS Zoetis $155.41 / -1.14 (-0.73%) 02/16/21 Zoetis sees FY21 EPS $4.36-$4.46 , consensus $4.26Zoetis 02/16/21 Zoetis reports Q4 EPS 91c, consensus 87c 11/05/20 Zoetis sees FY20 EPS $3.76-$3.81 , consensus $3.64 11/05/20 Zoetis reports Q3 EPS $1.10, consensus 91c SAGE Sage Therapeutics $85.02 / +1.45 (+1.74%) 02/24/21 Sage Therapeutics reports Q4 EPS $18.19, consensus (35c) 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) QTNT Quotient $4.49 / -0.06 (-1.32%) 02/01/21 Quotient sees FY21 total product sales of Alba by Quotient $33.5M-$34M 02/01/21 Quotient sees Q4 Alba by Quotient product sales $8.3M-$8.8M 02/01/21 Quotient reports Q3 EPS (29c), consensus (29c) 11/02/20 Quotient sees FY21 revenue $32M-$34M, consensus $34.86M QGEN Qiagen $50.02 / -0.33 (-0.66%) 02/09/21 Qiagen backs FY21 EPS view $2.42-$2.46, consensus $2.40 02/09/21 Qiagen reports Q4 EPS 68c, consensus 65c 12/08/20 Qiagen sees FY21 adj. EPS $2.42-$2.46 CER, consensus $2.40 12/08/20 Qiagen raises FY20 adj. EPS view to $2.13-$2.14 CER from $2.07-$2.09 CER PFE Pfizer $33.49 / -0.335 (-0.99%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 01/11/21 Pacific Biosciences sees Q4 revenue $27M, consensus $23.69M 11/02/20 Pacific Biosciences reports Q3 EPS (14c), consensus (13c) OTRK Ontrak $59.13 / -3.3 (-5.29%) 03/01/21 Ontrak sees FY21 revenue $100M, consensus $165.05M 03/01/21 Ontrak reports Q4 EPS (7c), consensus (30c) 11/05/20 Ontrak reports Q3 EPS (36c), consensus (35c) OCUL Ocular Therapeutix $18.40 / +0.27 (+1.49%) 11/05/20 Ocular Therapeutix reports Q3 EPS (21c), consensus (24c) 10/07/20 Ocular Therapeutix reports preliminary Q3 revenue $5.8M-$5.9M, consensus $3.91M GBT Global Blood Therapeutics $42.60 / -0.885 (-2.04%) 02/24/21 Global Blood Therapeutics reports Q4 EPS ($1.00) , consensus (94c) 11/05/20 Global Blood Therapeutics reports Q3 EPS ,(97c) consensus (73c) EXEL Exelixis $21.70 / -0.26 (-1.18%) 02/10/21 Exelixis backs FY21 revenue view $1.15B-$1.25B, consensus $1.2B 02/10/21 Exelixis reports Q4 adjusted EPS 14c, consensus 5c 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M DVAX Dynavax $8.75 / +0.595 (+7.30%) 02/25/21 Dynavax reports Q4 EPS (14c), consensus (24c) 11/05/20 Dynavax reports Q3 EPS 4c, consensus (20c) CHRS Coherus Biosciences $16.22 / +0.97 (+6.36%) 11/05/20 Coherus Biosciences reports Q3 EPS 47c, consensus 41c CERS Cerus $6.14 / -0.325 (-5.03%) 02/25/21 Cerus reports Q4 EPS (9c), consensus (9c) 01/11/21 Cerus sees Q4 product revenue $28.2M,consensus $31.6M 10/29/20 Cerus narrows FY20 product revenue view to $89M-$91M from $89M-$93M 10/29/20 Cerus reports Q3 EPS (8c), consensus (10c) BLFS BioLife Solutions $39.29 / +0.07 (+0.18%) 11/05/20 BioLife Solutions reports Q3 non-GAAP EPS 2c, consensus (2c) BIIB Biogen $272.68 / -4.95 (-1.78%) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 03/01/21 Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) 11/05/20 Axsome Therapeutics reports Q3 EPS (61c), consensus (57c) ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) 02/16/21 Arcutis Biotherapeutics reports Q4 EPS (79c), consensus (88c) 11/05/20 Arcutis Biotherapeutics reports Q3 EPS ($1.01), consensus (90c) ALNY Alnylam $147.94 / +1.4 (+0.96%) 02/11/21 Alnylam sees FY21 product revenue $610M-$660M 02/11/21 Alnylam reports Q4 non-GAAP EPS ($1.60), consensus ($1.76) 11/05/20 Alnylam reports Q3 EPS ($1.58), consensus ($1.66) ACAD Acadia $49.00 / +1.605 (+3.39%) 02/24/21 Acadia sees FY21 revenue $510M-$550M, consensus $676.18M 02/24/21 Acadia reports Q4 EPS (42c), consensus (47c) 11/04/20 Acadia backs FY20 NUPLAZID net sales view of $430M-$450M 11/04/20 Acadia reports Q3 EPS (54c), consensus (38c) 03 Feb 16 Dec 11 Nov 14 Oct 02 Oct 11 Sep 12 Aug 02 Jul 22 May 20 May ZTS QGEN PFE PACB BIIB ALNY ZTS Zoetis $155.41 / -1.14 (-0.73%) 09/12/20 Elanco stock well positioned for gains, Barron's says QGEN Qiagen $50.02 / -0.33 (-0.66%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports 02/08/21 Qiagen jumps after Bloomberg says Quidel made preliminary approach 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports PFE Pfizer $33.49 / -0.335 (-0.99%) 02/25/21 Johnson & Johnson one-dose COVID-19 vaccine approved by Bahrain, Reuters says 02/19/21 Pfizer to use additional capacity to boost vaccine output, Bloomberg says 02/19/21 BioNTech, Pfizer vaccine 85% effective after first dose, FT reports 02/17/21 Moderna to supply EU with another 150M vaccine doses in 2021, FT reports PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 02/23/21 Sources claim Softbank plans 'billions' in investment in biotech, Bloomberg says 02/10/21 SoftBank to invest $900M in Pacific Biosciences, WSJ reports 01/08/21 SoftBank has taken 6% stake in Pacific Biosciences, Bloomberg reports 01/08/21 Pacific Biosciences jumps after Bloomberg says SoftBank takes 6% stake BIIB Biogen $272.68 / -4.95 (-1.78%) 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says ALNY Alnylam $147.94 / +1.4 (+0.96%) 11/23/20 Alnylam gets FDA approval for Oxlumo, Bloomberg reports SAGE QTNT QGEN PFE PACB OCUL GBT EXEL DVAX BLFS BIIB AXSM ARQT SAGE Sage Therapeutics $85.02 / +1.45 (+1.74%) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers QTNT Quotient $4.49 / -0.06 (-1.32%) 11/02/20 Fly Intel: Pre-market Movers 09/09/20 Fly Intel: After-Hours Movers QGEN Qiagen $50.02 / -0.33 (-0.66%) 02/09/21 Fly Intel: After-Hours Movers 02/08/21 Fly Intel: Wall Street's top stories for Monday 11/11/20 Fly Intel: After-Hours Movers PFE Pfizer $33.49 / -0.335 (-0.99%) 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/18/21 Fly Intel: Wall Street's top stories for Thursday 02/18/21 Fly Intel: Wall Street's top stories at midday PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 11/03/20 Fly Intel: Pre-market Movers 10/02/20 Fly Intel: Pre-market Movers OCUL Ocular Therapeutix $18.40 / +0.27 (+1.49%) 12/28/20 Fly Intel: Pre-market Movers 12/15/20 Fly Intel: Pre-market Movers 12/14/20 Fly Intel: After-Hours Movers 10/13/20 Fly Intel: After-Hours Movers GBT Global Blood Therapeutics $42.60 / -0.885 (-2.04%) 02/24/21 Fly Intel: After-Hours Movers 02/16/21 Bluebird bio slides after pausing sickle cell studies 11/06/20 Fly Intel: Wall Street's top stories for Friday 11/06/20 Fly Intel: Wall Street's top stories at midday EXEL Exelixis $21.70 / -0.26 (-1.18%) 02/10/21 Fly Intel: After-Hours Movers DVAX Dynavax $8.75 / +0.595 (+7.30%) 02/26/21 Fly Intel: Wall Street's top stories for Friday 02/26/21 Fly Intel: Wall Street's top stories at midday 12/04/20 Fly Intel: Pre-market Movers 10/13/20 Fly Intel: Pre-market Movers BLFS BioLife Solutions $39.29 / +0.07 (+0.18%) 11/30/20 Fly Insider: Merrimack, Catalent among weeks notable insider trades BIIB Biogen $272.68 / -4.95 (-1.78%) 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 01/29/21 Fly Intel: Wall Street's top stories for Friday AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 12/01/20 Fly Intel: Pre-market Movers ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) 02/16/21 Fly Insider: Power REIT, Amphastar among week's notable insider trades 02/01/21 Fly Intel: After-Hours Movers 10/12/20 Fly Insider: Element Solutions, Sunrun among week's notable insider trades 09/29/20 Fly Intel: After-Hours Movers 13:00 Today Biopharmaceuticals 03/02/21 41st Annual Healthcare Virtual Conference 03/16/21 31st Annual Healthcare Virtual Conference 03/01/21 Axsome Therapeutics - AXSM 03/09/21 Ontrak - OTRK 03/11/21 Ocular Therapeutix - OCUL 03/24/21 Arthritis Advisory Committee and Drug Safety & Risk Mgmt Committee Meeting 04/03/21 PDUFA Date for NUPLAZID (Pimavanserin) 06/07/21 PDUFA Date for Aducanumab 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 03/05/21 Pfizer 00:00 Today Global Blood Therapeutics 03/18/21 Sage Therapeutics 04/15/21 Sage Therapeutics BIIB BIIB Biogen $272.68 / -4.95 (-1.78%) 09/15/20 Alexion strength attributed to takeover speculation QGEN PFE PACB OTRK DVAX BIIB ARQT QGEN Qiagen $50.02 / -0.33 (-0.66%) 10/14/20 Call spread buyer crosses wide spread in Qiagen 09/16/20 Largest borrow rate increases among liquid names PFE Pfizer $33.49 / -0.335 (-0.99%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PACB Pacific Biosciences $30.57 / -0.59 (-1.89%) 01/08/21 Pacific Biosciences call volume above normal and directionally bullish 11/02/20 Pacific Biosciences options imply 18.3% move in share price post-earnings OTRK Ontrak $59.13 / -3.3 (-5.29%) 10/12/20 Largest borrow rate increases among liquid names 09/16/20 Ontrak put volume heavy and directionally bearish 09/15/20 Ontrak put volume heavy and directionally bearish DVAX Dynavax $8.75 / +0.595 (+7.30%) 02/19/21 Dynavax call volume above normal and directionally bullish BIIB Biogen $272.68 / -4.95 (-1.78%) 01/29/21 Early notable gainers among liquid option names on January 29th 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th ARQT Arcutis Biotherapeutics $34.11 / +0.01 (+0.03%) 01/21/21 Eighteen new option listings and one option delisting on January 21st

Earnings	Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) » 07:32 03/01/21 03/01 07:32 03/01/21 07:32 BHVN Biohaven Pharmaceutical $84.92 / +1.57 (+1.88%) Reports Q4 revenue… Reports Q4 revenue $35.1M, consensus $28.23M. ShowHide Related Items >><< Company News Street Research Earnings Events BHVN Biohaven Pharmaceutical $84.92 / +1.57 (+1.88%) 02/22/21 Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains 01/25/21 Biohaven sees Q4 NURTEC ODT net product revenue $35M 01/19/21 Biohaven Pharmaceutical falls -9.2% 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial BHVN Biohaven Pharmaceutical $84.92 / +1.57 (+1.88%) 01/25/21 Piper Sandler Piper recommends buying Biohaven Pharmaceutical shares at current levels 01/19/21 Canaccord Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord 01/19/21 Mizuho Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho 01/19/21 H.C. Wainwright Biohaven price target lowered to $111 from $121 at H.C. Wainwright BHVN Biohaven Pharmaceutical $84.92 / +1.57 (+1.88%) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) 03/02/21 41st Annual Healthcare Virtual Conference 03/01/21 Biohaven Pharmaceutical - BHVN
Hot Stocks	Axsome Therapeutics announces 2021 anticipated milestones » 07:04 03/01/21 03/01 07:04 03/01/21 07:04 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) Anticipated Milestones… Anticipated Milestones NDA Submissions: AXS-07 for the acute treatment of migraine, submission early 2Q 2021. Clinical Trial Readouts: Phase 2 MERIT trial of AXS-05 in TRD, topline data 2H 2021. Clinical Trial Initiations: Phase 3 trial of AXS-12 in the treatment of narcolepsy 2Q 2021. FDA Meetings: AXS-14 for fibromyalgia 2Q 2021; AXS-05 for smoking cessation 3Q 2021. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 03/01/21 Axsome Therapeutics expects cash to fund operations into at least 2024 01/04/21 Myovant Sciences names David Marek as CEO, succeeding Lynn Seely 12/31/20 Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05 12/31/20 Axsome Therapeutics announces results from Phase 3 MOVEMENT trial of AXS-07 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Jefferies Axsome Therapeutics initiated with a Buy at Jefferies 12/15/20 Mizuho Axsome Therapeutics initiated with a Buy at Mizuho 12/03/20 Cantor Fitzgerald Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 03/01/21 Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) 11/05/20 Axsome Therapeutics reports Q3 EPS (61c), consensus (57c) AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 12/01/20 Fly Intel: Pre-market Movers 03/02/21 41st Annual Healthcare Virtual Conference 03/01/21 Axsome Therapeutics - AXSM
Hot Stocks	Axsome Therapeutics expects cash to fund operations into at least 2024 » 07:03 03/01/21 03/01 07:03 03/01/21 07:03 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) Axsome expects that its… Axsome expects that its operating expenses will increase year over year in 2021 to support continued pipeline advancement and build-out of the commercial function. Axsome believes that its cash at December 31, 2020, along with the remaining committed capital from the $225 million term loan facility, is sufficient to fund anticipated operations, based on the current operating plan which includes costs for the commercial launch of AXS-05 in MDD and AXS-07 in migraine, into at least 2024. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/04/21 Myovant Sciences names David Marek as CEO, succeeding Lynn Seely 12/31/20 Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05 12/31/20 Axsome Therapeutics announces results from Phase 3 MOVEMENT trial of AXS-07 12/08/20 Axsome Therapeutics reports 'positive' results from COMET-SI trial of AXS-05 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Jefferies Axsome Therapeutics initiated with a Buy at Jefferies 12/15/20 Mizuho Axsome Therapeutics initiated with a Buy at Mizuho 12/03/20 Cantor Fitzgerald Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 03/01/21 Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) 11/05/20 Axsome Therapeutics reports Q3 EPS (61c), consensus (57c) AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 12/01/20 Fly Intel: Pre-market Movers 03/02/21 41st Annual Healthcare Virtual Conference 03/01/21 Axsome Therapeutics - AXSM
Earnings	Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) » 07:02 03/01/21 03/01 07:02 03/01/21 07:02 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) "The focused… "The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer's disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "So far this year, we have submitted to the FDA the NDA for AXS-05 in major depressive disorder, and are nearing submission of the NDA for AXS-07 in the acute treatment of migraine, which is expected early in the second quarter. Our focus for the remainder of the year will be on the regulatory activities surrounding these NDAs, launch readiness to ensure a successful transition to commercialization, assuming product approvals, and continued advancement of the rest of our differentiated late-stage CNS pipeline." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/04/21 Myovant Sciences names David Marek as CEO, succeeding Lynn Seely 12/31/20 Axsome Therapeutics initiates ACCORD Phase 3 trial of AXS-05 12/31/20 Axsome Therapeutics announces results from Phase 3 MOVEMENT trial of AXS-07 12/08/20 Axsome Therapeutics reports 'positive' results from COMET-SI trial of AXS-05 AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 01/08/21 Fly Intel: Top five analyst initiations 01/08/21 Jefferies Axsome Therapeutics initiated with a Buy at Jefferies 12/15/20 Mizuho Axsome Therapeutics initiated with a Buy at Mizuho 12/03/20 Cantor Fitzgerald Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 11/05/20 Axsome Therapeutics reports Q3 EPS (61c), consensus (57c) AXSM Axsome Therapeutics $67.52 / -1.04 (-1.52%) 12/01/20 Fly Intel: Pre-market Movers 03/02/21 41st Annual Healthcare Virtual Conference 03/01/21 Axsome Therapeutics - AXSM
Hot Stocks	Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains » 07:33 02/22/21 02/22 07:33 02/22/21 07:33 BHVN Biohaven Pharmaceutical $82.92 / +0.68 (+0.83%) Biohaven Pharmaceutical… Biohaven Pharmaceutical Holding Company announced that a hyperimmune globulin mimic developed with Biohaven's proprietary MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the "English" and "South African" variants. The preliminary experiments, conducted by Biohaven Labs and an academic collaborator demonstrated that BHV-1200 substantially reduced viral entry into cells. Accelerated development of the COVID-19 MATE program has been supported by the Bill and Melinda Gates Foundation. Vlad Coric M.D., CEO of Biohaven commented, "The battle against COVID-19 -like the virus itself-is dynamic and ever changing. Prophylactic and therapeutic agents with broad specificity against current and future strains will be essential in this ongoing fight to beat the virus. Results from our recent preclinical testing are an exciting advancement for this platform technology, and shows that our lead novel MATE conjugate, BHV-1200, exhibits broad and potent antiviral activity against not only wild type SARS-CoV-2 spike protein but also against mutations of growing clinical relevance, such as those associated with reduced susceptibility to therapeutic monoclonal antibodies and recent SARS-CoV-2 strains." Dr. Coric added, "We believe that BHV-1200 could lead to enhanced efficacy and other benefits over convalescent plasma and alternative antibody-based approaches. Biohaven is excited to advance BHV-1200 into a full clinical development program. We are deeply grateful to the vision and critical funding support provided by The Bill & Melinda Gates Foundation that has accelerated this novel technology towards the clinic." ShowHide Related Items >><< Company News Street Research Earnings Events BHVN Biohaven Pharmaceutical $82.92 / +0.68 (+0.83%) 01/25/21 Biohaven sees Q4 NURTEC ODT net product revenue $35M 01/19/21 Biohaven Pharmaceutical falls -9.2% 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial 01/07/21 Biohaven Pharmaceutical acquires Kleo Pharmaceuticals, forms Biohaven Labs BHVN Biohaven Pharmaceutical $82.92 / +0.68 (+0.83%) 01/25/21 Piper Sandler Piper recommends buying Biohaven Pharmaceutical shares at current levels 01/19/21 Canaccord Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord 01/19/21 Mizuho Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho 01/19/21 H.C. Wainwright Biohaven price target lowered to $111 from $121 at H.C. Wainwright BHVN Biohaven Pharmaceutical $82.92 / +0.68 (+0.83%) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) 03/02/21 41st Annual Healthcare Virtual Conference

On The Fly

News and insights, exclusive to thefly.com

09:55	Fly Intel: Top five analyst initiations»
09:55	Fly Intel: Top five analyst downgrades»
09:55	Fly Intel: Top five analyst upgrades»
08:53	Immunovant jumps afrer majority holder Roivant says evaluating buyout»
20:01	Fly Intel: Top five weekend stock stories»

View all On The Fly Stories »

Upcoming
Events (10)

INFU	InfuSystem - INFU
KLDO ...	3rd Annual Microbiome Medicines Virtual Summit
NTLA ...	Global Healthcare Virtual Conference 2021
ABNB ...	Media, Internet and Telecom Virtual Conference
RYN ...	Global Property Virtual Conference
AKAM ...	2nd Annual Software Investor Virtual Day
KRP	Kimbell Royalty Partners
PBH	Prestige Consumer
IDYA	Ideaya Biosciences
RGEN	Repligen

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial